Your session is about to expire
← Back to Search
Sugammadex vs Neostigmine for Postoperative Weakness After Kidney Transplant
Study Summary
This trial is testing two different medications to see which one works better at reversing muscle paralysis at the end of kidney transplant surgery, in order to reduce weakness and breathing problems after surgery.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a lung, muscle, or other condition that greatly limits your ability to breathe properly and perform physical activities, such as climbing stairs.You are pregnant.Your body weight is very high and your BMI is above 40.
- Group 1: Neostigmine
- Group 2: Sugammadex
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential hazards have been identified for individuals taking Sugammadex?
"Due to it being a Phase 4 trial, Sugammadex has already been approved and thus is marked with the highest safety rating of 3."
What are Sugammadex's primary therapeutical applications?
"Sugammadex is the most typical treatment for neuromuscular blockade, though it may be employed to address post-operative intestinal atony, denture retention, and myasthenia gravis as well."
Are enrollees still being taken in for this research endeavor?
"Current information found on clinicaltrials.gov confirms that this trial is actively seeking enrolment, having been first posted on February 2nd 2021 and last updated on October 17th 2022."
Are there any additional experiments concerning Sugammadex that have been completed?
"Currently, there are 15 studies analyzing the efficacy of Sugammadex with 1 trial at Phase 3. The initial trials for this drug commenced in Rochester, Minnesota but now 51 different sites offer it as part of their clinical trials."
Does this study permit participants aged under 20 years old?
"This trial is seeking volunteers that are over 18 years of age and younger than 90."
What are the eligibility criteria for participating in this trial?
"This study is seeking 100 volunteers aged between 18 and 90 who have had postoperative residual curarization, with the intention of undergoing kidney transplantation surgery at the University of Colorado Hospital. To be considered for enrolment in this experiment, recipients must satisfy all age requirements (18 or older)."
How many individuals are contributing to this clinical experiment?
"Affirmative, clinicaltrials.gov's information attests to the fact that this medical trial is currently enrolling participants. It was launched on February 2nd 2021 with a recent update done in October 17th 2022 and it seeks 100 patients from one location."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger